The global humanized mouse and rat model market is witnessing strong momentum, driven by the increasing complexity of drug discovery and the rising demand for personalized medicine. Valued at approximately USD 255.8 million in 2024, the market is projected to reach USD 409.8 million by 2030, expanding at a CAGR of 8.2%. This growth reflects the expanding role of advanced preclinical models in improving the success rate of therapeutics, particularly in oncology, immunology, and rare diseases.
Humanized animal models—especially mice and rats—are engineered to carry human genes, tissues, or immune systems, allowing researchers to simulate human biological responses more accurately. These models are becoming indispensable in bridging the gap between in vitro research and clinical trials, significantly enhancing translational outcomes.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955
Rising Demand in Drug Discovery and Development
One of the primary drivers of the humanized mouse and rat model market is the increasing reliance on these models in drug discovery research. As pharmaceutical and biotechnology companies focus on developing targeted therapies, especially immunotherapies, the need for reliable preclinical models has intensified. Humanized models enable researchers to evaluate how therapeutic candidates interact with human immune systems, offering deeper insights into efficacy and safety before clinical trials.
In immuno-oncology, for instance, these models play a critical role in studying tumor-immune interactions and predicting patient responses to checkpoint inhibitors and other novel therapies. The growing number of approvals for cancer immunotherapies has further reinforced the importance of humanized models, as regulatory agencies increasingly require robust preclinical validation.
Expanding Role of CRISPR and Genetic Engineering
The emergence of CRISPR gene-editing technology has revolutionized the development of humanized models. By enabling precise genetic modifications, CRISPR has made it faster, more cost-effective, and highly scalable to create customized animal models. This advancement is unlocking new opportunities for market players, as researchers can now develop disease-specific models with greater accuracy.
CRISPR-based innovations are particularly valuable in studying genetic disorders, rare diseases, and complex conditions such as neurodegenerative diseases. The ability to replicate human disease pathways at a molecular level is significantly enhancing research outcomes and accelerating the pace of therapeutic innovation.
Dominance of Humanized Mouse Models
Among model types, humanized mouse models (hu-mice) dominate the market and are expected to maintain their leadership throughout the forecast period. This dominance is largely attributed to advancements in genetic engineering techniques such as gene targeting and gene editing.
Within this segment, genetic humanized mouse models account for the largest revenue share. These models are widely used for safety testing, pharmacokinetic and pharmacodynamic studies (PK/PD), and efficacy analysis of new drug candidates. Their ability to mimic human immune responses makes them highly valuable in evaluating biologics, vaccines, and cell and gene therapies.
Additionally, cell-based humanized mouse models are gaining traction for their role in studying immune cell interactions and disease progression. Together, these subsegments are strengthening the overall adoption of humanized mouse models across research settings.
Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955
Oncology Leads Application Segments
By application, oncology represents the largest segment in the humanized mouse and rat model market. The rising global burden of cancer, coupled with increased investments in cancer research, has driven the demand for advanced preclinical models.
Humanized models are particularly effective in oncology research, as they allow scientists to study tumor biology in a human-like immune environment. This capability is crucial for developing next-generation therapies such as CAR-T cells, monoclonal antibodies, and immune checkpoint inhibitors.
Beyond oncology, these models are also gaining importance in infectious diseases, autoimmune disorders, and regenerative medicine. However, the scale and funding associated with cancer research continue to position oncology as the leading application area.
Growing Importance of CROs and CDMOs
Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are emerging as the fastest-growing end-user segment in the market. These organizations play a critical role in outsourcing preclinical research services, enabling pharmaceutical and biotech companies to streamline operations and reduce costs.
CROs and CDMOs utilize humanized mouse and rat models to conduct efficacy studies, toxicology assessments, and biomarker analysis. By offering specialized expertise and infrastructure, these organizations are becoming key contributors to market growth.
Moreover, the increasing trend of outsourcing preclinical and clinical research activities is driving demand for high-quality humanized models. As drug pipelines become more complex, CROs are investing heavily in advanced model systems to meet evolving client requirements.
Asia Pacific: The Fastest-Growing Regional Market
Geographically, Asia Pacific is expected to register the highest growth rate during the forecast period. Countries such as China and India are witnessing a surge in pharmaceutical R&D activities, supported by favorable government policies and increasing investments in healthcare infrastructure.
The region is also becoming a global hub for outsourced research services, attracting multinational pharmaceutical companies seeking cost-effective solutions. The growing number of CROs, expanding biotech ecosystem, and rising focus on precision medicine are further fueling market expansion in Asia Pacific.
In addition, the increasing prevalence of chronic diseases and the need for innovative therapies are encouraging research institutions and companies to adopt advanced preclinical models, including humanized mice and rats.
Enquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=131763955
Competitive Landscape and Key Players
The humanized mouse and rat model market is highly competitive, with several global and regional players focusing on innovation, partnerships, and expansion strategies. Leading companies are investing in advanced technologies to enhance model accuracy and scalability.
Key players include Charles River Laboratories, The Jackson Laboratory (JAX), Taconic Biosciences, Crown Biosciences (a JSR Corporation company), Champions Oncology, Inotiv, genOway, and Cyagen Biosciences, among others. These companies are actively expanding their product portfolios and strengthening their global presence through collaborations and acquisitions.
Specialized providers such as Hera BioLabs and GemPharmatech are also gaining traction by offering customized models tailored to specific research needs. This growing ecosystem of providers is contributing to the rapid evolution of the market.
Future Outlook
The future of the humanized mouse and rat model market looks promising, driven by continuous advancements in biotechnology, increasing R&D investments, and the growing need for precision medicine. As drug development becomes more targeted and complex, the demand for accurate and reliable preclinical models will continue to rise.
Technologies such as CRISPR, single-cell analysis, and multi-omics integration are expected to further enhance the capabilities of humanized models, enabling deeper insights into disease mechanisms and therapeutic responses. In conclusion, the humanized mouse and rat model market is set to play a pivotal role in shaping the future of drug discovery and biomedical research. With expanding applications, technological innovations, and increasing global demand, this market is poised for sustained growth in the coming years.
